Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Aligos Therapeutics Inc (ALGS)
Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,658
  • Shares Outstanding, K 42,940
  • Annual Sales, $ 13,910 K
  • Annual Income, $ -96,050 K
  • 60-Month Beta 2.50
  • Price/Sales 3.44
  • Price/Cash Flow N/A
  • Price/Book 0.46
Trade ALGS with:

Options Overview Details

View History
  • Implied Volatility 333.24% ( +333.24%)
  • Historical Volatility 45.42%
  • IV Percentile 83%
  • IV Rank 41.73%
  • IV High 749.47% on 05/09/22
  • IV Low 35.16% on 06/14/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 1
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 528
  • Open Int (30-Day) 632

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.47
  • Number of Estimates 3
  • High Estimate -0.45
  • Low Estimate -0.50
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +44.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0000 +2.00%
on 03/30/23
1.7200 -40.70%
on 03/01/23
-0.4400 (-30.14%)
since 02/28/23
3-Month
0.8401 +21.41%
on 12/29/22
2.4100 -57.68%
on 01/17/23
+0.1201 (+13.35%)
since 12/28/22
52-Week
0.8401 +21.41%
on 12/29/22
2.4100 -57.68%
on 01/17/23
-1.0900 (-51.66%)
since 03/28/22

Most Recent Stories

More News
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

ALGS : 1.0200 (-1.92%)
BLUE : 3.16 (+0.64%)
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -1.09% and 16.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANAB : 21.83 (+3.17%)
ALGS : 1.0200 (-1.92%)
Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards?

In the absence of a marketed product, Entera Bio (ENTX) is expected to provide an update on its pipeline candidates, mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively....

BGNE : 217.76 (-0.20%)
ENTX : 1.1900 (-2.46%)
ALLO : 5.07 (+2.01%)
ALGS : 1.0200 (-1.92%)
Illumina (ILMN) Misses Q4 Earnings Estimates

Illumina (ILMN) delivered earnings and revenue surprises of -26.32% and 1.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ILMN : 228.51 (+1.44%)
ALGS : 1.0200 (-1.92%)
Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs

Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%. Shares fall.

SNDX : 21.14 (+2.32%)
EDIT : 7.25 (+3.13%)
ALGS : 1.0200 (-1.92%)
CELU : 0.6051 (-0.80%)
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

ALGS : 1.0200 (-1.92%)
Aligos Therapeutics to Present at the Jefferies 2022 Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

ALGS : 1.0200 (-1.92%)
Horizon (HZNP) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

Horizon's (HZNP) earnings and revenues trump estimates in the first quarter of 2022.

VRTX : 312.72 (+0.18%)
HZNP : 109.17 (-0.06%)
VYGR : 7.76 (+0.52%)
ALGS : 1.0200 (-1.92%)
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company...

ALGS : 1.0200 (-1.92%)
Editas' (EDIT) Q1 Loss Narrows, Revenues Beat Estimates

Editas (EDIT) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates. Focus on lead candidate, EDIT-101.

VRTX : 312.72 (+0.18%)
VYGR : 7.76 (+0.52%)
EDIT : 7.25 (+3.13%)
ALGS : 1.0200 (-1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.

See More

Key Turning Points

3rd Resistance Point 1.3267
2nd Resistance Point 1.2533
1st Resistance Point 1.1467
Last Price 1.0200
1st Support Level 0.9667
2nd Support Level 0.8933
3rd Support Level 0.7867

See More

52-Week High 2.4100
Fibonacci 61.8% 1.8103
Fibonacci 50% 1.6251
Fibonacci 38.2% 1.4398
Last Price 1.0200
52-Week Low 0.8401

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar